Drug Development Clinical Trials Vaccine Development Acquisitions Cancer Treatment Immunotherapy Oncology Metabolic Health Clinical Research Biosimilars Gene Therapy Manufacturing Research and Development Biopharmaceuticals Regulatory Affairs Clinical Development Drug Discovery Cancer Therapies mRNA Technology Vaccine Production Stock Market Mergers and Acquisitions Biologics Partnerships Immuno-oncology Contract Manufacturing Cancer Therapy RNA Interference Company Performance RNA Medicines Psychedelics Alzheimer's Disease Genetic Research Roivant Sciences Vaccines Company Developments Corporate Governance Neuromodulators Biontech Corporate Finance Obesity Treatment Plasma Fractionation Biotech Companies Cancer Treatments Vertex Pharmaceuticals Contract Development and Manufacturing Corporate Partnerships Biologics Manufacturing Company Activities mRNA Therapies COVID-19 Vaccines Patents MEI Pharma Pet Pharmaceuticals Investment in AI Biotech Stocks Drug Delivery Systems RNA Drugs Collaborations Weight Loss Obesity Treatments Company Operations Autoimmune Diseases Cancer Research Radiopharmaceuticals AstraZeneca Arrowhead Pharmaceuticals Vaccine Manufacturing Immunology Strategic Partnerships Biomanufacturing Market Competition REGENXBIO Company Acquisitions Investment Plasma Products Market Strategy Product Development Financial Results Company Strategy Therapies Intellectual Property Vaccine Candidates Neurodegenerative Diseases Corporate Strategy Biopharmaceutical Companies Licensing Company News Immunotherapies Drug Delivery Psychedelic Therapies Genetic Medicine Investment Strategies Neurology Research Funding Licensing Agreements Market Analysis Business Development Antibody Development Global Operations
Want to see what podcasts are saying about this topic? Search across 165K+ podcasts. Explore Radar
Because the Phase 1 candidate engaged its target but failed to show clinical benefit, the company will shift to proprietary programs to stretch cash into the second half of 2029.
